Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients

Eur J Immunol. 2020 Dec;50(12):2013-2024. doi: 10.1002/eji.202048915. Epub 2020 Nov 9.

Abstract

The characterization of cell-mediated and humoral adaptive immune responses to SARS-CoV-2 is fundamental to understand COVID-19 progression and the development of immunological memory to the virus. In this study, we detected T-cells reactive to SARS-CoV-2 proteins M, S, and N, as well as serum virus-specific IgM, IgA, IgG, in nearly all SARS-CoV-2 infected individuals, but not in healthy donors. Virus-reactive T cells exhibited signs of in vivo activation, as suggested by the surface expression of immune-checkpoint molecules PD1 and TIGIT. Of note, we detected antigen-specific adaptive immune response both in asymptomatic and symptomatic SARS-CoV-2 infected subjects. More importantly, symptomatic patients displayed a significantly higher magnitude of both cell-mediated and humoral adaptive immune response to the virus, as compared to asymptomatic individuals. These findings suggest that an uncontrolled adaptive immune response contribute to the development of the life-threatening inflammatory phase of the disease. Finally, this study might open the way to develop effective vaccination strategies.

Keywords: Antibodies; Cellular immunology; Infectious diseases; Memory cells; Virology.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antibodies, Viral / immunology*
  • COVID-19 / immunology*
  • Carrier State / immunology*
  • Carrier State / virology
  • Female
  • Humans
  • Immunity, Humoral*
  • Programmed Cell Death 1 Receptor / immunology
  • Receptors, Immunologic / immunology
  • SARS-CoV-2 / immunology*
  • T-Lymphocytes / immunology*
  • Viral Proteins / immunology

Substances

  • Antibodies, Viral
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Immunologic
  • TIGIT protein, human
  • Viral Proteins